WIDeCAD: a guided internet- and mobile-based self-help intervention for patients facing coronary artery disease (CAD) and depression - a randomized controlled pilot trial

WIDeCAD: a guided internet- and mobile-based self-help intervention for patients facing coronary artery disease (CAD) and depression - a randomized controlled pilot trial - WIDeCAD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00012546

Enrollment

Registered

2017-07-17

Start date

2017-06-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I20-I25 F30-F39

Interventions

Group 1: Participants receive treatment as usual and immediately access to a guided (e-coach

trained psychologists) internet- and mobile-based cognitive-behavioral selfhelp-programm against depression

the program consists of 7 lessons, 6 out of 9 optional lessons and one booster session after four weeks

participants work on 1-2 lessons per week and will receive feedback after each lesson by e-coaches (trained psychologists)

main components of the program include psychoeducation, behavioural activation, problem solving and cognitive restructuring. Group 2: waitlist control group: participants will receive standard care an

participants in the waitlist control group will work on the program without guidance.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: diagnosis of a coronary artery disease, PHQ-9 score = 5; access to internet

Exclusion criteria

Exclusion criteria: Acute suicidality; concurrent or life-time diagnosis of schizophrenia, psychosis or bipolar disorder

Design outcomes

Primary

Measure	Time frame
feasibility: recruitment strategies (quantification of recruitmentstrategies, drop-out) acceptance (ZUF-8 , time of measurement: T2, adverse events (INEP , time of measurement: T2(=2 months after randomization), adherence (discontinuation rate, time of measurement: T2) T2=2 months after randomisation	—

Secondary

Measure	Time frame
depressive symptom severity (PHQ-9, T1 and T2), anxiety severity (GAD-7, T1 and T2), quality of life (AQoL, T1 and T2) and fear of progression (PA-F, T1 and T2), disease-specific strains (CSS-classification (questionnaire (=self-report), T1 and T2) T1=Measurement after screening (T0) T2=2 months after randomisation	—

Countries

Austria, Germany, Switzerland

Contacts

Public ContactEileen Bendig

Abteilung für klinische Psychologie und Psychotherapie, Institut für Psychologie und Pädagogik,Universität Ulm

widecad-studie@uni-ulm.de0731 5032807

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026